TPD & Induced Proximity Summit Leaderboard
  • Tuesday, June 23, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 81

Author

Pharma Journalist 8887 posts 0 comments

Pfizer Signs Exclusive Licensing Deal with 3SBio

May 20, 2025
Pfizer Inc. announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the…
Read More...

Celebrating a Decade of Innovation: The 10th Microbiome Movement Drug Development Summit

May 20, 2025
The Microbiome Movement Summit returns in 2025 for its milestone 10th edition, marking a decade of groundbreaking progress and collaborative advancement in microbiome science. This…
Read More...

Septerna, Novo Nordisk Partner on Oral Treatments for Obesity and Cardiometabolic Diseases

May 16, 2025
Septerna, Inc. and Novo Nordisk announced an exclusive global collaboration and license agreement to discover, develop and commercialise oral small molecule medicines for obesity, type…
Read More...

FDA Accepts BioCryst’s NDA for ORLADEYO in Young HAE Patients

May 16, 2025
BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for the use of oral, once-daily ORLADEYO …
Read More...

FDA Approves EMRELIS for Advanced NSCLC with High c-Met

May 16, 2025
AbbVie announced that EMRELIS (telisotuzumab vedotin-tllv) has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with…
Read More...

Stylus Medicine Launches to Advance Precision In Vivo CAR-T Therapies

May 15, 2025
Stylus Medicine, Inc. (“Stylus”), a biotechnology company dedicated to developing transformative in vivo genetic medicines, emerges from stealth with $85 million in financing. Stylus’…
Read More...

GSK to Acquire Efimosfermin for Steatotic Liver Disease

May 15, 2025
GSK plc and Boston Pharmaceuticals announced that they have entered into an agreement under which GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Efimosfermin is…
Read More...

Tempus, Boehringer Ingelheim Launch Cancer Collaboration

May 15, 2025
Tempus AI, Inc. announced a new strategic collaboration to advance Boehringer Ingelheim’s growing cancer pipeline. The new, multi-year collaboration builds on foundational work the two…
Read More...

AbbVie, ADARx Partner on Next-Gen siRNA Therapies

May 15, 2025
AbbVie and ADARx Pharmaceuticals, a late clinical-stage biotechnology company developing next-generation RNA therapeutics, announced a collaboration and license option agreement to…
Read More...

Recipharm and PLG Form Partnership to Accelerate Drug Development

May 14, 2025
Recipharm and ProductLife Group (PLG) announced a strategic collaboration aimed at supporting (bio)pharmaceutical companies in accelerating time to clinical trials and market approval…
Read More...
Prev Next
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
In Vivo Cell Engineering & Gene Editing Summit
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Voro and Alloy Partner on Safer Cancer Immunotherapies
  • uniQure Reports Early Promise for Epilepsy Gene Therapy
  • Boltz and Takeda Expand AI-Powered Drug Discovery Efforts
  • SK Pharmteco Partners With OTXL for Rare Disease Therapies
  • Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.